Whitepaper: Drug repurposing strategies to shorten timelines
This whitepaper explores drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
List view / Grid view
This whitepaper explores drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
Researchers have developed a novel platform technology, iVAX, that could enable the decentralised bioproduction of conjugate vaccines and enhance vaccination rates in developing nations.
18 November 2021 | By
The agreement enables the EU and European Economic Area (EEA) countries to donate Moderna's COVID-19 vaccine to low-income countries.
Download this whitepaper to discover the latest developments and research in QA/QC for biologic therapies via exclusive articles, interviews and application notes.
This application aims to replace the two separate compendial methods for the impurity analysis of gabapentin with one single HPLC method.
This webinar considers the fundamental importance of water system control within pharma processing and the best control and monitoring practices.
This whitepaper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods will not solve.
Kris Sterkens, Company Group Chairman of Janssen EMEA and Managing Director of Janssen Pharmaceutica considers how alterations made to COVID-19 vaccine development procedures could benefit future drug development pipelines.
Telstar promotes innovative aseptic production solutions in a setting marked by the new GMP Annex 1.
In this webinar, discover how an innovative 2-in-1 method for material analysis accelerates visual and chemical particle analysis in the pharmaceutical industry.
This flyer explains step-by-step how to perform your root cause analysis more efficiently, reliably and cost-effectively with a 2-in-1 solution for visual and chemical particle analysis.
In this eGuide you will learn about an innovative 2-in-1 method for materials analysis and how your analysis for contamination identification and root cause analysis will benefit.
The US Food and Drug Administration has authorised the emergency use of COVID-19 vaccine Comirnaty in children aged five to 11 years.
EMA's drug safety committee (PRAC) assessed risks with COVID-19 vaccines and identified no risk of death with Imbruvica and ACE inhibitors.
The European Medicines Agency (EMA)'s human medicines committee (CHMP) concludes that a booster dose of Spikevax can be administered in adults aged 18 or over.